Related references
Note: Only part of the references are listed.A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Elliott Vichinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Elisa Magrin et al.
BLOOD (2019)
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
Mary Eapen et al.
LANCET HAEMATOLOGY (2019)
Emerging Genetic Therapy for Sickle Cell Disease
Stuart H. Orkin et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Marilyn J. Telen et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Divya S. Vinjamur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study
John F. Tisdale et al.
BLOOD (2018)
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
K. I. Ataga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treating sickle cell disease by targeting HbS polymerization
William A. Eaton et al.
BLOOD (2017)
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Daniel P. Dever et al.
NATURE (2016)
A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15
Stephan Menzel et al.
NATURE GENETICS (2007)
Linus Pauling and sickle cell disease
WA Eaton
BIOPHYSICAL CHEMISTRY (2003)
Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
C May et al.
NATURE (2000)
Share Paper
